Indications for Carbidopa/Levodopa Orally Disintegrating Tabs:
Discontinue levodopa at least 12 hrs before starting carbidopa/levodopa. Dissolve tabs on tongue. ≥18yrs: initially one 25/100 tab 3 times daily, or one 10/100 tab 3–4 times daily; increase every 1–2 days up to either 2 tabs of 25/100 or 2 tabs of 10/100 4 times daily. Patients taking levodopa >1500mg/day: initially one 25/250 tab 3–4 times daily; usual max carbidopa 200mg/day.
<18yrs: not recommended.
Carbidopa/Levodopa Orally Disintegrating Tabs Contraindications:
During or within 14 days of nonselective MAOIs. Narrow-angle glaucoma. Undiagnosed skin lesions. History of melanoma.
Carbidopa/Levodopa Orally Disintegrating Tabs Warnings/Precautions:
Severe cardiovascular or pulmonary disease. Asthma. Renal, hepatic, or endocrine disorders. History of peptic ulcer or MI with residual arrhythmias. Suicidal tendencies. Psychosis. Orthostatic hypotension. Chronic wide-angle glaucoma. Monitor renal, hepatic and cardiovascular function, intraocular pressure, blood counts. May stain body fluids. Pregnancy (Cat.C). Nursing mothers.
Carbidopa/Levodopa Orally Disintegrating Tabs Classification:
Dopa-decarboxylase inhibitor + dopamine precursor.
Carbidopa/Levodopa Orally Disintegrating Tabs Interactions:
See Contraindications. Antagonized by phenothiazines, butyrophenones, risperidone, phenytoin, papaverine, isoniazid; possibly iron, high protein diets, excessive gastric acidity. Orthostatic hypotension with selegiline, antihypertensives. May be affected by metoclopramide. Hypertension, dyskinesia with tricyclics. May cause false (+) urinary ketone or Coombs test or false (–) urinary glucose (glucose oxidase) test.
Dyskinesias, GI upset, CNS disturbances (eg, hallucinations, confusion, depression, dizziness, headache, insomnia, somnolence), syncope, hypo- or hypertension, dyspnea, on-off phenomena, blepharospasm (may indicate excess dose), urine discoloration, lab abnormalities; rare: neuroleptic malignant syndrome.
Formerly known under the brand name Parcopa.